Aim: Preeclampsia (PE) is a dangerous condition that affects 3–5% of pregnancies and has a substantial risk of death and morbidity for both mothers and newborns. The processes behind the etiology of PE are not entirely known, despite the fact that it is the primary cause of illness and death among mothers globally. In order to further understand the correlations between these parameters, this study will look at the levels and presence of anti-carbonicanhydrase (CA) I and II antibodies, total oxidant capacity (TOC), total antioxidant capacity (T-AOC), and malondialdehyde (MDA) in early PE.
Material and Method: The research analyzed 30 pregnant women with early PE and 30 normal pregnant women as the control group. Serum levels of anti-CAI (pg/mL), anti-CAII (ng/mL), MDA (nmol/mL), TOS (U/mL), T-AOC (U/mL) were measured and compared between the two groups.
Results: Significant variations were noted in the amount of anti-CA I, anti-CA II, MDA, TOS, and T-AOC (both p<0.05) between the control group and the early PE group. More specifically, oxidative stress indicators were changed and increased levels of anti-CA I and anti-CA II were seen in the early PE group in comparison with the control group.
Conclusion: The findings show that elevated amounts of anti-CAI and anti-CAII antibodies may serve as predictive markers for early PE. The significant differences in oxidative stress parameters further support the oxidative stress involvement in the pathogenesis of early PE. However, more extensive Research is required to validate these results and clarify the mechanisms underlying PE.
Antioxidants carbonic anhydrase malondialdehyde oxidants oxidative stress preeclampsia
Ethical approval for the study was obtained from the İnonu University Faculty of Medicine Clinical Research Ethics Committee (ethical approval number:2021/113). The researchers committed to comply with the principles of the World Medical Association Declaration of Helsinki (including the recruitments adopted in 2008) and the Good Clinical Practice (GCP) Guide, which was enacted on December 29, 1995, as an annex to the circular numbered 51748 by the Turkish Ministry of Health.
This research was supported by the Scientific Research Supportment Commitee of Malatya Turgut Ozal University, Malatya, Turkiye (Project no: .2021/2)
2021/2
2021/2
| Birincil Dil | İngilizce |
|---|---|
| Konular | Metabolik Tıp |
| Bölüm | Klinik Araştırma |
| Yazarlar | |
| Proje Numarası | 2021/2 |
| Gönderilme Tarihi | 23 Ağustos 2024 |
| Kabul Tarihi | 17 Eylül 2024 |
| Yayımlanma Tarihi | 24 Eylül 2024 |
| Yayımlandığı Sayı | Yıl 2024 Cilt: 6 Sayı: 3 |
Chief Editors
Prof. Dr. Berkant Özpolat, MD
Department of Thoracic Surgery, Ufuk University, Dr. Rıdvan Ege Hospital, Ankara, Türkiye
Editors
Prof. Dr. Sercan Okutucu, MD
Department of Cardiology, Ankara Lokman Hekim University, Ankara, Türkiye
Assoc. Prof. Dr. Süleyman Cebeci, MD
Department of Ear, Nose and Throat Diseases, Gazi University Faculty of Medicine, Ankara, Türkiye
Field Editors
Assoc. Prof. Dr. Doğan Öztürk, MD
Department of General Surgery, Manisa Özel Sarıkız Hospital, Manisa, Türkiye
Assoc. Prof. Dr. Birsen Doğanay, MD
Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Türkiye
Assoc. Prof. Dr. Sonay Aydın, MD
Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Türkiye
Language Editors
PhD, Dr. Evin Mise
Department of Work Psychology, Ankara University, Ayaş Vocational School, Ankara, Türkiye
Dt. Çise Nazım
Department of Periodontology, Dr. Burhan Nalbantoğlu State Hospital, Lefkoşa, North Cyprus
Statistics Editor
Dr. Nurbanu Bursa, PhD
Department of Statistics, Hacettepe University, Faculty of Science, Ankara, Türkiye
Scientific Publication Coordinator
Kübra Toğlu
argistyayincilik@gmail.com
Franchise Owner
Argist Yayıncılık
argistyayincilik@gmail.com
Publisher: Argist Yayıncılık
E-mail: argistyayincilik@gmail.com
Phone: 0312 979 0235
GSM: 0533 320 3209
Address: Kızılırmak Mahallesi Dumlupınar Bulvarı No:3 C-1 160 Çankaya/Ankara, Türkiye
Web: www.argistyayin.com.tr